Neuronal autoantibodies in patients initially diagnosed with psychiatric disorders or neurological disorders. (Neuroscience 2026) - Sep 27, 2026 - Abstract #PSTR175.14 / V3; Pres time: Nov 16, 2026; 01:00 PM - 05:00 PM; Location: WCC Halls A-C; "Most of positive patients were received steroids, plasmapheresis, high-dose immunoglobulin or rituximab and the prognosis was generally well...The different results in test method and test specimen should be careful. Results for Neural Cell Adhesion Molecule 1 (NCAM1), neurexin 1α (NRXN1α), and Dopamine-2 receptor (D2R) antibodies may also be presented."
Clinical • Alzheimer's Disease • Bipolar Disorder • CNS Disorders • Cognitive Disorders • Dementia • Depression • Epilepsy • Mental Retardation • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry • Psychosomatic Disorders • Schizophrenia • Sleep Disorder • NCAM1 • NRXN1
|
|
M. TAKAKI1; K. HINOTSU2; H. KAWAI3; T. ASADA2; Y. OHYA2; A. YOKODE2; S. SAKAMOTO1
|